Revvity, Inc. (NYSE:RVTY) Insider Tajinder S. Vohra Sells 2,154 Shares

Revvity, Inc. (NYSE:RVTY) insider Tajinder S. Vohra sold 2,154 shares of Revvity stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total value of $262,206.42. Following the sale, the insider now directly owns 19,652 shares in the company, valued at approximately $2,392,237.96. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Revvity Stock Performance

RVTY stock opened at $121.51 on Friday. The stock has a market capitalization of $14.99 billion, a PE ratio of 100.42, a price-to-earnings-growth ratio of 3.35 and a beta of 1.05. The company has a current ratio of 2.27, a quick ratio of 1.98 and a debt-to-equity ratio of 0.40. The stock’s 50 day simple moving average is $121.40 and its 200 day simple moving average is $112.27. Revvity, Inc. has a 12-month low of $79.50 and a 12-month high of $128.15.

Revvity (NYSE:RVTY) last announced its earnings results on Monday, July 29th. The company reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of $1.12 by $0.10. The business had revenue of $691.70 million during the quarter, compared to analyst estimates of $690.33 million. Revvity had a net margin of 6.26% and a return on equity of 7.34%. The company’s quarterly revenue was down 2.5% compared to the same quarter last year. During the same period in the previous year, the business earned $1.21 EPS. As a group, research analysts forecast that Revvity, Inc. will post 4.75 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, November 8th. Shareholders of record on Friday, October 18th will be paid a dividend of $0.07 per share. The ex-dividend date is Friday, October 18th. This represents a $0.28 dividend on an annualized basis and a yield of 0.23%. Revvity’s dividend payout ratio is presently 23.14%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on RVTY. TD Cowen boosted their price target on Revvity from $130.00 to $141.00 and gave the stock a “buy” rating in a research report on Tuesday, July 30th. Wells Fargo & Company began coverage on Revvity in a research report on Tuesday, August 27th. They issued an “equal weight” rating and a $130.00 price target on the stock. Leerink Partners began coverage on Revvity in a research report on Monday, July 8th. They issued an “outperform” rating and a $125.00 price target on the stock. Barclays boosted their price target on Revvity from $115.00 to $125.00 and gave the stock an “equal weight” rating in a research report on Tuesday, July 30th. Finally, Citigroup boosted their price target on Revvity from $135.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, July 30th. Eight investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Revvity currently has an average rating of “Moderate Buy” and an average target price of $125.53.

Institutional Investors Weigh In On Revvity

Hedge funds have recently added to or reduced their stakes in the stock. Rothschild Investment LLC purchased a new stake in Revvity during the 2nd quarter valued at $25,000. EverSource Wealth Advisors LLC increased its stake in shares of Revvity by 74.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 392 shares of the company’s stock worth $41,000 after purchasing an additional 167 shares in the last quarter. Fairfield Financial Advisors LTD purchased a new stake in shares of Revvity in the 2nd quarter worth $43,000. Family Firm Inc. purchased a new stake in shares of Revvity in the 2nd quarter worth $43,000. Finally, EntryPoint Capital LLC purchased a new stake in shares of Revvity in the 1st quarter worth $48,000. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.